Increasing evidence has suggested that iron accumulation plays an important role in the onset and development of Alzheimer’s disease (AD). However, the potential mechanism remains unclear.
Objective:
The present study investigated the associations of cerebrospinal fluid (CSF) ferritin, an indicator for brain iron load, with neurodegenerative and inflammatory changes in AD.
Methods:
The study involved 302 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). They were classified as normal controls (A–T–N–, n = 48), AD continuum (A+TN–, n = 46; A+TN+, n = 166), and suspected non-AD pathology (A–TN+, n = 42), according to the amyloid/tau/neurodegeneration (ATN) system. Group comparisons of CSF ferritin among groups were performed using one-way ANOVA. Linear regression models were used to test the relationships between CSF ferritin and cognitive assessments, and the associations between CSF ferritin and other biomarkers, respectively.
Results:
We found that CSF ferritin showed significant differences among the ATN groups, with higher concentration in more advanced categories (A+TN+). Furthermore, CSF ferritin level was independently related to cognitive performance (MMSE, ADAS-Cog13, and ADNI-mem). Linear regression analysis indicated positive relationships between CSF ferritin and phosphorylated tau and total tau, rather than Aβ42. Significant associations were revealed between CSF ferritin and inflammatory proteins, including TNF-α, TNFR1, TNFR2, ICAM1, VCAM1, TGF-β1, IL-9, and IP-10, respectively.
Conclusion:
Our results provide new insight into iron dysfunction in AD pathology and highlight elevated brain iron as a possible mechanism of neurodegeneration and neuroinflammation along AD continuum.
EichlerT, ThyrianJR, HertelJ, KohlerL, WuchererD, DreierA, MichalowskyB, TeipelS, HoffmannW (2014) Rates of formal diagnosis in people screened positive for dementia in primary care: Results of the DelpHi-Trial. J Alzheimers Dis42, 451–458.
2.
ScheltensP, De StrooperB, KivipeltoM, HolstegeH, ChetelatG, TeunissenCE, CummingsJ, van der FlierWM (2021) Alzheimer’s disease. Lancet397, 1577–1590.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCJ, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
5.
ZhangN, YuX, XieJ, XuH (2021) New insights into the role of ferritin in iron homeostasis and neurodegenerative diseases. Mol Neurobiol58, 2812–2823.
6.
PetersDG, ConnorJR, MeadowcroftMD (2015) The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer’s disease: Two sides of the same coin. Neurobiol Dis81, 49–65.
7.
JakariaM, BelaidiAA, BushAI, AytonS (2021) Ferroptosis as a mechanism of neurodegeneration in Alzheimer’s disease. J Neurochem159, 804–825.
8.
EverettJ, CollingwoodJF, Tjendana-TjhinV, BrooksJ, LermyteF, Plascencia-VillaG, Hands-PortmanI, DobsonJ, PerryG, TellingND (2018) Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer’s disease subjects. Nanoscale10, 11782–11796.
9.
BushAI (2013) The metal theory of Alzheimer’s disease. J Alzheimers Dis33(Suppl 1), S277–S281.
10.
Plascencia-VillaG, PonceA, CollingwoodJF, Arellano-JimenezMJ, ZhuX, RogersJT, BetancourtI, Jose-YacamanM, PerryG (2016) High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer’s disease. Sci Rep6, 24873.
11.
FosterCM, KennedyKM, DaughertyAM, RodrigueKM (2020) Contribution of iron and Abeta to age differences in entorhinal and hippocampal subfield volume. Neurology95, e2586–e2594.
12.
BulkM, KenkhuisB, van der GraafLM, GoemanJJ, NatteR, van der WeerdL (2018) Postmortem T2*-weighted MRI imaging of cortical iron reflects severity of Alzheimer’s disease. J Alzheimers Dis65, 1125–1137.
13.
SpotornoN, Acosta-CabroneroJ, StomrudE, LampinenB, StrandbergOT, van WestenD, HanssonO (2020) Relationship between cortical iron and tau aggregation in Alzheimer’s disease. Brain143, 1341–1349.
14.
LaneD, AytonS, BushAI (2018) Iron and Alzheimer’s disease: An update on emerging mechanisms. J Alzheimers Dis64, S379–S395.
15.
HentzeMW, MuckenthalerMU, GalyB, CamaschellaC (2010) Two to tango: Regulation of Mammalian iron metabolism. Cell142, 24–38.
16.
BrosseronF, KleemannK, KolbeCC, SantarelliF, Castro-GomezS, TacikP, LatzE, JessenF, HenekaMT (2021) Interrelations of Alzheimer’s disease candidate biomarkers neurogranin, fatty acid-binding protein 3 and ferritin to neurodegeneration and neuroinflammation. J Neurochem157, 2210–2224.
17.
FernandezT, Martinez-SerranoA, CussoL, DescoM, Ramos-GomezM (2018) Functionalization and characterization of magnetic nanoparticles for the detection of ferritin accumulation in Alzheimer’s disease. ACS Chem Neurosci9, 912–924.
18.
MuellerSG, WeinerMW, ThalLJ, PetersenRC, JackCR, JagustW, TrojanowskiJQ, TogaAW, BeckettL (2005) Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement1, 55–66.
CranePK, CarleA, GibbonsLE, InselP, MackinRS, GrossA, JonesRN, MukherjeeS, CurtisSM, HarveyD, WeinerM, MungasD (2012) Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav6, 502–516.
21.
VassilakiM, AakreJA, KremersWK, MielkeMM, GedaYE, AlhuraniRE, DuttT, MachuldaMM, KnopmanDS, VemuriP, ColomaPM, SchaubleB, LoweVJ, JackCR, PetersenRC, RobertsRO (2019) The association of multimorbidity with preclinical ad stages and SNAP in cognitively unimpaired persons. J Gerontol A Biol Sci Med Sci74, 877–883.
22.
AytonS, FauxNG, BushAI (2015) Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. Nat Commun6, 6760.
23.
MontgomerySL, BowersWJ (2012) Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol7, 42–59.
24.
ZlokovicBV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron57, 178–201.
25.
HickmanSE, AllisonEK, ElKJ (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci28, 8354–8360.
AytonS, DioufI, BushAI (2018) Evidence that iron accelerates Alzheimer’s pathology: A CSF biomarker study. J Neurol Neurosurg Psychiatry89, 456–460.
29.
LovellMA, XiongS, XieC, DaviesP, MarkesberyWR (2004) Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis6, 673–681; discussion 659-671.
30.
RaoSS, AdlardPA (2018) Untangling tau and iron: Exploring the interaction between iron and tau in neurodegeneration. Front Mol Neurosci11, 276.
31.
WanW, CaoL, KalionisB, MurthiP, XiaS, GuanY (2019) Iron deposition leads to hyperphosphorylation of tau and disruption of insulin signaling. Front Neurol10, 607.
32.
GuoC, WangP, ZhongML, WangT, HuangXS, LiJY, WangZY (2013) Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int62, 165–172.
33.
EverettJ, BrooksJ, LermyteF, O’ConnorPB, SadlerPJ, DobsonJ, CollingwoodJF, TellingND (2020) Iron stored in ferritin is chemically reduced in the presence of aggregating Abeta(1-42). Sci Rep10, 10332.
34.
RapoportM, DawsonHN, BinderLI, VitekMP, FerreiraA (2002) Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A99, 6364–6369.
35.
ShiptonOA, LeitzJR, DworzakJ, ActonCE, TunbridgeEM, DenkF, DawsonHN, VitekMP, Wade-MartinsR, PaulsenO, Vargas-CaballeroM (2011) Tau protein is required for amyloid beta-induced impairment of hippocampal long-term potentiation. J Neurosci31, 1688–1692.
36.
LiX, LeiP, TuoQ, AytonS, LiQX, MoonS, VolitakisI, LiuR, MastersCL, FinkelsteinDI, BushAI (2015) Enduring elevations of hippocampal amyloid precursor protein and iron are features of beta-amyloid toxicity and are mediated by tau. Neurotherapeutics12, 862–873.
37.
EdisonP, BrooksDJ (2018) Role of neuroinflammation in the trajectory of Alzheimer’s disease and in vivo quantification using PET. J Alzheimers Dis64, S339–S351.
38.
UrrutiaPJ, BorquezDA, NunezMT (2021) Inflaming the brain with iron. Antioxidants (Basel)10, 61.
39.
FestaL, GutoskeyCJ, GrazianoA, WaterhouseBD, MeucciO (2015) Induction of interleukin-1beta by human immunodeficiency virus-1 viral proteins leads to increased levels of neuronal ferritin heavy chain, synaptic injury, and deficits in flexible attention. J Neurosci35, 10550–10561.
40.
RauchmannBS, SadlonA, PerneczkyR (2020) Soluble TREM2 and inflammatory proteins in Alzheimer’s disease cerebrospinal fluid. J Alzheimers Dis73, 1615–1626.
41.
TarkowskiE, AndreasenN, TarkowskiA, BlennowK (2003) Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry74, 1200–1205.
42.
WangJ, SongN, JiangH, WangJ, XieJ (2013) Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons. Biochim Biophys Acta1832, 618–625.
43.
ChaudharyS, AshokA, McDonaldD, WiseAS, KritikosAE, RanaNA, HardingCV, SinghN (2021) Upregulation of local hepcidin contributes to iron accumulation in Alzheimer’s disease brains. J Alzheimers Dis82, 1487–1497.
44.
NemethE, TuttleMS, PowelsonJ, VaughnMB, DonovanA, WardDM, GanzT, KaplanJ (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science306, 2090–2093.
45.
KelleherRJ, SoizaRL (2013) Evidence of endothelial dysfunction in the development of Alzheimer’s disease: Is Alzheimer’s a vascular disorder?Am J Cardiovasc Dis3, 197–226.
EstradaLD, Oliveira-CruzL, CabreraD (2018) Transforming growth factor beta type i role in neurodegeneration: Implications for Alzheimer’s disease. Curr Protein Pept Sci19, 1180–1188.
48.
LedeboerA, BreveJJ, WierinckxA, van der JagtS, BristowAF, LeysenJE, TildersFJ, Van DamAM (2002) Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. Eur J Neurosci16, 1175–1185.
49.
BrosseronF, TraschutzA, WidmannCN, KummerMP, TacikP, SantarelliF, JessenF, HenekaMT (2018) Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease. Alzheimers Res Ther10, 25.
50.
PalanimuthuD, PoonR, SahniS, AnjumR, HibbsD, LinHY, BernhardtPV, KalinowskiDS, RichardsonDR (2017) A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer’s disease. Eur J Med Chem139, 612–632.
51.
JanelidzeS, ZetterbergH, MattssonN, PalmqvistS, VandersticheleH, LindbergO, van WestenD, StomrudE, MinthonL, BlennowK, HanssonO (2016) CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol3, 154–165.
